Tom Marcucci

Kedrion Biopharma, Inc. operates as an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Its services include Italian partnership, contract manufacturing, technology transfer, and biological safety center. The company was founded in 2011 and is headquartered in Fort Lee, NJ.

Kedrion Biopharma, Inc. operates as an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Its services include Italian partnership, contract manufacturing, technology transfer, and biological safety center. The company was founded in 2011 and is headquartered in Fort Lee, NJ.

Kedrion Biopharma, Inc. operates as an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Its services include Italian partnership, contract manufacturing, technology transfer, and biological safety center. The company was founded in 2011 and is headquartered in Fort Lee, NJ.

Kedrion Biopharma, Inc. operates as an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Its services include Italian partnership, contract manufacturing, technology transfer, and biological safety center. The company was founded in 2011 and is headquartered in Fort Lee, NJ.

Kedrion Biopharma, Inc. operates as an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Its services include Italian partnership, contract manufacturing, technology transfer, and biological safety center. The company was founded in 2011 and is headquartered in Fort Lee, NJ.